Get the Stockscreener App
1.17
4.88%
-0.06
After Hours:
1.23
0.06
+5.13%
NanoViricides Inc stock is traded at $1.17, with a volume of 143.40K.
It is down -4.88% in the last 24 hours and down -23.53% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.23
Open:
$1.22
24h Volume:
143.40K
Relative Volume:
0.46
Market Cap:
$16.93M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-1.6714
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
-2.50%
1M Performance:
-23.53%
6M Performance:
-40.91%
1Y Performance:
+0.86%
1-Day Range:
$1.16
$1.2382
1-Week Range:
$1.1221
$1.35
52-Week Range:
$1.0297
$3.59
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.17 | 16.93M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
NNVC’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387 - Proactive financial news
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts - Proactive Investors UK
NanoViricides (NYSE:NNVC) Trading Down 1.8% – What’s Next? - Defense World
NanoViricides to present at MicroCap Conference 2025 in Atlantic City - Proactive Investors UK
Game-Changing Antiviral Drug Shows 'Superior Results' Against Multiple Viruses$10B Market Potential - StockTitan
NanoViricides advances antiviral drug with Phase II Clinical trial to Combat MPox - Proactive Investors USA
NanoViricides taps clinical research organization for Phase II trial of NV-387 - Proactive Investors UK
NanoViricides Engages CRO for Phase II Clinical Trial - Oil City Derrick
NanoViricides to present antiviral drug pipeline at Biotech Showcase 2025 - Proactive Investors Australia
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 - Oil City Derrick
NanoViricides CEO discusses NV-387’s broad spectrum promiseICYMI - Proactive Investors Australia
NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats - Proactive Investors Australia
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals - AccessWire
NanoViricides (NYSE:NNVC) Trading Down 5% – Should You Sell? - Defense World
First US bird flu fatality raises alarms over mutations in H5N1 virus - Proactive Investors USA
NanoViricides CEO discusses groundbreaking broad-spectrum antiviral treatment - Proactive Investors UK
NanoViricides, Inc. Files Quarterly ReportReports a Strong Cash Position Sufficient for Initial C - AOL
NanoViricides sees NV-387 as a key defense against bird flu pandemic - Proactive Investors UK
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape - Oil City Derrick
NanoViricides' NV-387 Shows Breakthrough 88% Survival Rate Against H5N1 Bird Flu in Key Study - StockTitan
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America By Proactive Investors - Investing.com UK
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America - Proactive Investors UK
NanoViricides: Pioneering the Future of Antiviral Therapies - TechBullion
NanoViricides (AMEX:$NNVC) Leads Innovation In Broad-Spectrum Antiviral Therapies - Barchart
NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapies - openPR
NanoViricides (NYSE:NNVC) Rating Lowered to “Sell” at StockNews.com - Defense World
NanoViricides pushes NV-387 to Phase II trials - Proactive Investors Australia
NanoViricides' Antiviral Drug NV-387 Advances to Phase II Trials Amid Funding Needs - StockTitan
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical TrialMultiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID - Source ONE News
NanoViricides Inc (NNVC) Quarterly 10-Q Report - Quartz
NanoViricides pushes NV-387 to Phase II trials | NYSE-A:NNVC - Proactive Investors USA
NanoViricides: Fiscal Q1 Earnings Snapshot - San Antonio Express-News
NanoViricides to update on broad-spectrum antiviral drug at Spartan Capital Investors Conference - Proactive Investors Australia
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - Oil City Derrick
NanoViricides exec to showcase breakthrough antiviral technology at PODD Conference - Proactive financial news
NanoViricides President Dr. Diwan to Present at the PODD Conference - News-Press Now
NanoViricides exec to showcase breakthrough antiviral technology at PODD Conference | NYSE-A:NNVC - Proactive Investors USA
Can NanoViricides Inc (NNVC) Stock Rise to the Top of Healthcare Sector Tuesday? - InvestorsObserver
Interview with the President and Executive Chairman: NanoViricides, Inc. (NYSEAMERICAN:NNVC) - The Wall Street Transcript
NNVC - Insider Financial
Chronic Fatigue Syndrome Market Demand and Opportunities - openPR
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology - Oil City Derrick
Renaissance Technologies LLC Boosts Position in NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy - Insider Monkey
7 Best Nanotech Penny Stocks to Buy - Insider Monkey
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):